These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 35053463

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
    Mizuno R, Maruhashi T, Sugiura D, Shimizu K, Watada M, Okazaki IM, Okazaki T.
    Biochem Biophys Res Commun; 2019 Apr 09; 511(3):491-497. PubMed ID: 30771904
    [Abstract] [Full Text] [Related]

  • 3. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML.
    J Immunother Cancer; 2021 Oct 09; 9(10):. PubMed ID: 34706886
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.
    Liu L, Wu Y, Ye K, Cai M, Zhuang G, Wang J.
    Front Pharmacol; 2022 Oct 09; 13():924197. PubMed ID: 35865955
    [Abstract] [Full Text] [Related]

  • 6. Quantitative contributions of TNF receptor superfamily members to CD8+ T-cell responses.
    Nguyen J, Pettmann J, Kruger P, Dushek O.
    Mol Syst Biol; 2021 Nov 09; 17(11):e10560. PubMed ID: 34806839
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
    Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.
    Oncoimmunology; 2018 Nov 09; 7(2):e1380764. PubMed ID: 29308300
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
    Zhong Q, Zhu YM, Zheng LL, Shen HJ, Ou RM, Liu Z, She YL, Chen R, Li C, Huang J, Yao MD, Zhang Q, Liu S.
    Acta Haematol; 2018 Nov 09; 140(3):131-140. PubMed ID: 30253384
    [Abstract] [Full Text] [Related]

  • 12. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
    Moran AE, Kovacsovics-Bankowski M, Weinberg AD.
    Curr Opin Immunol; 2013 Apr 09; 25(2):230-7. PubMed ID: 23414607
    [Abstract] [Full Text] [Related]

  • 13. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD, Hirano N.
    Nat Med; 2018 Mar 09; 24(3):352-359. PubMed ID: 29400710
    [Abstract] [Full Text] [Related]

  • 14. 4-1BB Signaling Enhances Primary and Secondary Population Expansion of CD8+ T Cells by Maximizing Autocrine IL-2/IL-2 Receptor Signaling.
    Oh HS, Choi BK, Kim YH, Lee DG, Hwang S, Lee MJ, Park SH, Bae YS, Kwon BS.
    PLoS One; 2015 Mar 09; 10(5):e0126765. PubMed ID: 25962156
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
    Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M.
    J Immunother Cancer; 2019 Jul 19; 7(1):191. PubMed ID: 31324216
    [Abstract] [Full Text] [Related]

  • 17. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells.
    Dai Q, Han P, Qi X, Li F, Li M, Fan L, Zhang H, Zhang X, Yang X.
    Front Immunol; 2020 Jul 19; 11():539654. PubMed ID: 33281809
    [Abstract] [Full Text] [Related]

  • 18. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
    Wang Y, Zhong K, Ke J, Chen X, Chen Y, Shu W, Chen C, Hu S, Sun X, Huang H, Luo C, Liu L, Yang J, Zhang Y, Zhi H.
    Cytotherapy; 2021 Aug 19; 23(8):715-723. PubMed ID: 33863641
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-κB.
    Lubrano di Ricco M, Ronin E, Collares D, Divoux J, Grégoire S, Wajant H, Gomes T, Grinberg-Bleyer Y, Baud V, Marodon G, Salomon BL.
    Eur J Immunol; 2020 Jul 19; 50(7):972-985. PubMed ID: 32012260
    [Abstract] [Full Text] [Related]

  • 20. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Bovetti K, Manni S, Caruana I, Ciccone R, Del Bufalo F, Merli P, Vinti L, Girardi K, Ruggeri A, De Stefanis C, Pezzullo M, Giorda E, Scarsella M, De Vito R, Barresi S, Ciolfi A, Tartaglia M, Moretta L, Locatelli F, Quintarelli C, De Angelis B.
    Haematologica; 2021 Apr 01; 106(4):987-999. PubMed ID: 32381575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.